The partnership addresses a bottleneck in the biopharmaceutical sector where the yield and translation efficiency of mRNA therapies rely heavily on precise co-transcriptional capping. By leveraging the synthesis expertise of the Łukasiewicz-IChP, ExploRNA aims to ensure a reliable supply chain for developers working on genetic medicines. This move allows the company to support its partners from initial research phases through to full-scale commercialization.
Prof. Jacek Jemielity, CEO of ExploRNA, noted that securing this manufacturing capability validates the scalability of the company’s synthesis processes. The collaboration serves as a strategic move to stabilize the availability of premium-grade raw materials, which are essential for maintaining the quality standards required in modern vaccine and therapeutic development.
Comments (0)
No comments yet. Be the first!